{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:14:38Z","timestamp":1790396078003,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40262-021-01057-3","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T15:04:09Z","timestamp":1628175849000},"page":"143-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Infliximab Treatment Does Not Lead to Full TNF-\u03b1 Inhibition: A Target-Mediated Drug Disposition Model"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4020-4545","authenticated-orcid":false,"given":"David","family":"Ternant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Le Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Mulleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Picon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Willot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Passot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Bejan-Angoulvant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"issue":"7","key":"1057_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40262-020-00874-2","volume":"59","author":"A Bensalem","year":"2020","unstructured":"Bensalem A, Ternant D. Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications. Clin Pharmacokinet. 2020;59(7):857\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"1057_CR2","first-page":"14554","volume":"2020","author":"O Le Tilly","year":"2020","unstructured":"Le Tilly O, Bejan-Angoulvant T, Paintaud G, et al. Letter to Dreesen et al. on their article \u201cModelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn\u2019s disease\u201d: a comprehensive review of infliximab population pharmacokinetic modelling publications. Br J Clin Pharmacol. 2020;2020:14554.","journal-title":"Br J Clin Pharmacol"},{"key":"1057_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10928-019-09652-5","volume":"46","author":"SE Berends","year":"2019","unstructured":"Berends SE, van Steeg TJ, Ahsman MJ, et al. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. J Pharmacokinet Pharmacodyn. 2019;46:543\u201351.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1057_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2133\/dmpk.22.20","volume":"22","author":"Y Furuya","year":"2007","unstructured":"Furuya Y, Ozeki T, Takayanagi R, et al. Theory based analysis of anti-inflammatory effect of infliximab on Crohn\u2019s disease. Drug Metab Pharmacokinet. 2007;22:20\u20135. https:\/\/doi.org\/10.2133\/dmpk.22.20.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1057_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00296-010-1553-8","volume":"32","author":"K Kimura","year":"2012","unstructured":"Kimura K, Takayanagi R, Yokoyama H, et al. Theory-based analysis of anti-inflammatory effect of infliximab on Crohn\u2019s disease and rheumatoid arthritis. Rheumatol Int. 2012;32:145\u201350.","journal-title":"Rheumatol Int"},{"key":"1057_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/bdd.2198","volume":"40","author":"K Kimura","year":"2019","unstructured":"Kimura K, Yoshida A, Katagiri F, et al. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Biopharm Drug Dispos. 2019;40:250\u201361.","journal-title":"Biopharm Drug Dispos"},{"key":"1057_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2133\/dmpk.dmpk-13-rg-090","volume":"29","author":"K Kimura","year":"2014","unstructured":"Kimura K, Takayanagi R, Yokoyama H, et al. Theory-based analysis of the anti-inflammatory effect of TNF inhibitors on rheumatoid arthritis. Drug Metab Pharmacokinet. 2014;29:272\u20137. https:\/\/doi.org\/10.2133\/dmpk.dmpk-13-rg-090.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1057_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.365-2249.1990.tb03334.x","volume":"81","author":"TT MacDonald","year":"1990","unstructured":"MacDonald TT, Hutchings P, Choy MY, et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 1990;81:301\u20135. https:\/\/doi.org\/10.1111\/j.365-2249.1990.tb03334.x.","journal-title":"Clin Exp Immunol"},{"key":"1057_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/gut.32.8.913","volume":"32","author":"SH Murch","year":"1991","unstructured":"Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32:913\u20137. https:\/\/doi.org\/10.1136\/gut.32.8.913.","journal-title":"Gut"},{"key":"1057_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1155\/2014\/675108","volume":"2014","author":"M Schulz","year":"2014","unstructured":"Schulz M, Dotzlaw H, Neeck G. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-\u03b1 and its soluble receptors during the course of therapy with etanercept and infliximab. Biomed Res Int. 2014;2014:24.","journal-title":"Biomed Res Int"},{"key":"1057_CR11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/FTD.0000000000000389","volume":"39","author":"C Passot","year":"2017","unstructured":"Passot C, Pouw MF, Mulleman D, et al. Therapeutic drug monitoring of biopharmaceuticals may benefit from pharmacokinetic and pharmacokinetic-pharmacodynamic modeling. Ther Drug Monit. 2017;39:322\u20136.","journal-title":"Ther Drug Monit"},{"key":"1057_CR12","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00228-015-1942-8","volume":"71","author":"A Aubourg","year":"2015","unstructured":"Aubourg A, Picon L, Lecomte T, et al. A robust estimation of infliximab pharmacokinetic parameters in Crohn\u2019s disease. Eur J Clin Pharmacol. 2015;71:1541\u20132.","journal-title":"Eur J Clin Pharmacol"},{"key":"1057_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/19420862.2016.1216741","volume":"8","author":"C Passot","year":"2016","unstructured":"Passot C, Mulleman D, Bejan-Angoulvant T, et al. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. MAbs. 2016;8:1407\u201316.","journal-title":"MAbs"},{"key":"1057_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s40262-017-0621-6","volume":"57","author":"D Ternant","year":"2018","unstructured":"Ternant D, Passot C, Aubourg A, et al. Model-based therapeutic drug monitoring of infliximab using a single serum trough concentration. Clin Pharmacokinet. 2018;57:1173\u201384.","journal-title":"Clin Pharmacokinet"},{"key":"1057_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/art.39841","volume":"69","author":"T Bejan-Angoulvant","year":"2017","unstructured":"Bejan-Angoulvant T, Ternant D, Daoued F, et al. Brief report: relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis. Arthritis Rheumatol. 2017;69:108\u201313.","journal-title":"Arthritis Rheumatol"},{"key":"1057_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/FTD.0b013e3181cc6fef","volume":"32","author":"D Mulleman","year":"2010","unstructured":"Mulleman D, Chu Miow Lin D, Ducourau E, et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit. 2010;32:232\u20136.","journal-title":"Ther Drug Monit"},{"key":"1057_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4049\/jimmunol.1501780","volume":"196","author":"D Ternant","year":"2016","unstructured":"Ternant D, Arnoult C, Pugniere M, et al. IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding. J Immunol. 2016;196:607\u201313. https:\/\/doi.org\/10.4049\/jimmunol.1501780.","journal-title":"J Immunol"},{"key":"1057_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","volume":"30","author":"D Ternant","year":"2008","unstructured":"Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523\u20139. https:\/\/doi.org\/10.1097\/FTD.0b013e318180e300.","journal-title":"Ther Drug Monit"},{"key":"1057_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/01.ftd.0000189901.08684.4b","volume":"28","author":"D Ternant","year":"2006","unstructured":"Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169\u201374.","journal-title":"Ther Drug Monit"},{"key":"1057_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507\u201332.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1057_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1517\/17425250902992901","volume":"5","author":"L Gibiansky","year":"2009","unstructured":"Gibiansky L, Gibiansky E. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol. 2009;5:803\u201312. https:\/\/doi.org\/10.1517\/17425250902992901.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl. 2","key":"1057_CR22","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1186\/ar549","volume":"4","author":"RN Maini","year":"2002","unstructured":"Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4(Suppl. 2):S22\u20138. https:\/\/doi.org\/10.1186\/ar549.","journal-title":"Arthritis Res"},{"key":"1057_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/rheumatology\/41.3.329","volume":"41","author":"H Matsuno","year":"2002","unstructured":"Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA\/SCID mouse chimera. Rheumatology (Oxford). 2002;41:329\u201337. https:\/\/doi.org\/10.1093\/rheumatology\/41.3.329.","journal-title":"Rheumatology (Oxford)"},{"key":"1057_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/btt.009.3099","volume":"3","author":"A Perdriger","year":"2009","unstructured":"Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics. 2009;3:183\u201391. https:\/\/doi.org\/10.2147\/btt.009.3099.","journal-title":"Biologics"},{"key":"1057_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","volume":"131","author":"Z Kaymakcalan","year":"2009","unstructured":"Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308\u201316. https:\/\/doi.org\/10.1016\/j.clim.2009.01.002.","journal-title":"Clin Immunol"},{"key":"1057_CR26","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jmb.2007.10.034","volume":"374","author":"MS Kim","year":"2007","unstructured":"Kim MS, Lee SH, Song MY, et al. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol. 2007;374:1374\u201388. https:\/\/doi.org\/10.1016\/j.jmb.2007.10.034.","journal-title":"J Mol Biol"},{"key":"1057_CR27","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1124\/dmd.116.074807","volume":"45","author":"X Chen","year":"2017","unstructured":"Chen X, DuBois DC, Almon RR, et al. Interrelationships between infliximab and recombinant tumor necrosis factor-\u03b1 in plasma using minimal physiologically based pharmacokinetic models. Drug Metab Dispos. 2017;45:790\u20137.","journal-title":"Drug Metab Dispos"},{"key":"1057_CR28","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1080\/00365521.2020.1786852","volume":"55","author":"S Buhl","year":"2020","unstructured":"Buhl S, Dorn-Rasmussen M, Brynskov J, et al. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. Scand J Gastroenterol. 2020;55:884\u201390.","journal-title":"Scand J Gastroenterol"},{"key":"1057_CR29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/19420862.2017.1304869","volume":"9","author":"A Deora","year":"2017","unstructured":"Deora A, Hegde S, Lee J, et al. Transmembrane TNF-dependent uptake of anti-TNF antibodies. MAbs. 2017;9:680\u201395.","journal-title":"MAbs"},{"key":"1057_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2016.01.001","volume":"159","author":"CM Olesen","year":"2016","unstructured":"Olesen CM, Coskun M, Peyrin-Biroulet L, et al. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther. 2016;159:110\u20139.","journal-title":"Pharmacol Ther"},{"key":"1057_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1006\/cyto.995.0029","volume":"7","author":"BJ Scallon","year":"1995","unstructured":"Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251\u20139. https:\/\/doi.org\/10.1006\/cyto.995.0029.","journal-title":"Cytokine"},{"key":"1057_CR32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/jpet.301.2.418","volume":"301","author":"B Scallon","year":"2002","unstructured":"Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418\u201326. https:\/\/doi.org\/10.1124\/jpet.301.2.418.","journal-title":"J Pharmacol Exp Ther"},{"key":"1057_CR33","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.4049\/jimmunol.135.6.3972","volume":"135","author":"BA Beutler","year":"1985","unstructured":"Beutler BA, Milsark IW, Cerami A. Cachectin\/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985;135:3972\u20137.","journal-title":"J Immunol"},{"key":"1057_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF00253968","volume":"20","author":"PJ Creaven","year":"1987","unstructured":"Creaven PJ, Plager JE, Dupere S, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1987;20:137\u201344. https:\/\/doi.org\/10.1007\/BF00253968.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1057_CR35","first-page":"358","volume":"251","author":"A Greischel","year":"1989","unstructured":"Greischel A, Zahn G. Pharmacokinetics of recombinant human tumor necrosis factor alpha in rhesus monkeys after intravenous administration. J Pharmacol Exp Ther. 1989;251:358\u201361.","journal-title":"J Pharmacol Exp Ther"},{"key":"1057_CR36","first-page":"1180","volume":"39","author":"G Zahn","year":"1989","unstructured":"Zahn G, Greischel A. Pharmacokinetics of tumor necrosis factor alpha after intravenous administration in rats: dose dependence and influence of tumor necrosis factor beta. Arzneimittelforschung. 1989;39:1180\u20132.","journal-title":"Arzneimittelforschung"},{"key":"1057_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40262-018-0680-3","volume":"58","author":"D Ternant","year":"2019","unstructured":"Ternant D, Azzopardi N, Raoul W, et al. Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans. Clin Pharmacokinet. 2019;58:169\u201387.","journal-title":"Clin Pharmacokinet"},{"key":"1057_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/jisp.jisp_362_17","volume":"22","author":"S Thilagar","year":"2018","unstructured":"Thilagar S, Theyagarajan R, Sudhakar U, et al. Comparison of serum tumor necrosis factor-\u03b1 levels in rheumatoid arthritis individuals with and without chronic periodontitis: a biochemical study. J Indian Soc Peridontal. 2018;22:116\u201321. https:\/\/doi.org\/10.4103\/jisp.jisp_362_17.","journal-title":"J Indian Soc Peridontal."},{"key":"1057_CR39","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1136\/ard.2011.153023","volume":"70","author":"T Takeuchi","year":"2011","unstructured":"Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:1208\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1057_CR40","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/annrheumdis-2019-216169","volume":"79","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, Oba K, Koike T, et al. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Ann Rheum Dis. 2020;79:94\u2013102.","journal-title":"Ann Rheum Dis"},{"key":"1057_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10928-012-9260-6","volume":"39","author":"LA Peletier","year":"2012","unstructured":"Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn. 2012;39:429\u201351.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1057_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/bcp.12313","volume":"78","author":"D Ternant","year":"2014","unstructured":"Ternant D, Ducourau E, Perdriger A, et al. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol. 2014;78:118\u201328.","journal-title":"Br J Clin Pharmacol"},{"key":"1057_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/jcph.1732","volume":"61","author":"A Eser","year":"2021","unstructured":"Eser A, Reinisch W, Schreiber S, et al. Increased induction infliximab clearance predicts early antidrug antibody detection. J Clin Pharmacol. 2021;61:224\u201333.","journal-title":"J Clin Pharmacol"},{"key":"1057_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/apt.13299","volume":"42","author":"DJ Buurman","year":"2015","unstructured":"Buurman DJ, Maurer JM, Keizer RJ, et al. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharmacol Ther. 2015;42:529\u201339.","journal-title":"Aliment Pharmacol Ther"},{"key":"1057_CR45","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-015-0296-9","volume":"54","author":"D Ternant","year":"2015","unstructured":"Ternant D, Bejan-Angoulvant T, Passot C, et al. Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin Pharmacokinet. 2015;54:1107\u201323.","journal-title":"Clin Pharmacokinet"},{"key":"1057_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/19420862.2016.1238995","volume":"9","author":"S Ait-Oudhia","year":"2017","unstructured":"Ait-Oudhia S, Ovacik MA, Mager DE. Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. MAbs. 2017;9:15\u201328.","journal-title":"MAbs"},{"key":"1057_CR47","first-page":"1365","volume":"2011","author":"D Ternant","year":"2011","unstructured":"Ternant D, Mulleman D, Lauferon F, et al. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol. 2011;2011:1365\u20132125.","journal-title":"Br J Clin Pharmacol"},{"key":"1057_CR48","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1208\/s12248-016-9989-8","volume":"19","author":"H Edlund","year":"2017","unstructured":"Edlund H, Steenholdt C, Ainsworth MA, et al. Magnitude of increased infliximab clearance imposed by anti-infliximab antibodies in Crohn\u2019s disease is determined by their concentration. AAPS J. 2017;19:223\u201333.","journal-title":"AAPS J"},{"key":"1057_CR49","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946\u201364.","journal-title":"Clin Ther"},{"key":"1057_CR50","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/cpt.1429","volume":"106","author":"A Petitcollin","year":"2019","unstructured":"Petitcollin A, Brochard C, Siproudhis L, et al. Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases. Clin Pharmacol Ther. 2019;106:605\u201315.","journal-title":"Clin Pharmacol Ther"},{"key":"1057_CR51","unstructured":"Ternant D, Picon L, Cartron G, et al. Revisiting target-mediated elimination of therapeutic antibodies: the irreversible binding approximation. PAGE. 2019;28:abstract no. 9169. Available from: www.page-meeting.org\/?abstract=9169. Accessed 11 Jul 2021."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01057-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T17:28:39Z","timestamp":1673026119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01057-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01057-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"6 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was partly supported by the Higher Education and Research Ministry under the programme \u2018Investissements d\u2019avenir\u2019 Grant Agreement: LabEx MAbImprove ANR-10-LABX-53-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"David Ternant acted as a consultant and has given lectures on behalf of his institution for Amgen, Sanofi, Boehringer-Ingelheim and Novartis. Marc Pfister is a part-time consultant at Certara, outside the submitted work. Denis Mulleman has acted as a consultant and given lectures on behalf of his institution for Pfizer, Novartis and Grifols; he has been invited to attend an international congress by Janssen-Cilag. His institution received grants for research from the non-governmental organisation Lions Club Tours Val de France. Laurence Picon has acted as a consultant for Abbvie, Janssen-Cilag, Pfizer and Takeda, outside the submitted work. Stephanie Willot has given lectures to Abbvie, outside the submitted work. Theodora Bejan-Angoulvant reports support for travel to congresses from Servier and BMS, outside the submitted work. She has given lectures on behalf of her institution to Amgen and Sanofi, outside the submitted work. Gilles Paintaud has received grants for his research team from Roche Pharma, Chugai, Pfizer, Novartis and Sanofi-Genzyme. Olivier le Tilly, Christophe Passot, Thierry Lecomte and Gilbert Koch have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not sought in this retrospective analysis of routine patients, which is in accordance with institutional guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was not sought in this retrospective analysis of routine patients, which is in accordance with institutional guidelines.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data and material are available on request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code is available on request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"DT designed the research, analysed the data, interpreted the results and wrote the manuscript. MP, GP and GK participated in the data analysis and interpretation of the results and reviewed the manuscript. OT contributed to the data analysis and interpretation of the results and reviewed the manuscript. DM, LP, SW CP and TL participated in the data acquisition and reviewed the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}